Abstract:2033 Background: The risk of VTE is very high for patients with brain tumors, with Glioblastoma (GB) considered one of the most at risk cancers. The aim of this study is to describe the occurrence and associated risk factors for the development of VTE among GB (patients) pts. Methods: In this IRB approved retrospective study, our neuro-oncology longitudinal database was screened for pts with GB, who were treated with concurrent radiation and Temozolomide (TMZ) followed by adjuvant TMZ from 2005-2011. 543 pts were identified. Results: 134 (24.6%) pts developed VTE, with 139 documented events. 56 pts (42%) were diagnosed with deep vein thrombosis (DVT) , 27 pts (20%) with pulmonary emboli (PE) with no evidence of DVT, and 51 pts (38%) had both DVT and PE. The majority were diagnosed after starting adjuvant TMZ (61%) with a median time of 6.5 months from starting adjuvant TMZ (range 0.03-120) with only 22 (16%) pts developing VTE before starting post surgery treatment and 32(23%) during chemoradiation. At time of VTE diagnosis, 44 (32%) patients had stable disease, 61 (43%) were clinically or radiographically progressing and the rest were newly diagnosed or during concurrent treatment. 56 (40%) patients were admitted secondary to their VTE. Treatment with anticoagulation alone was given to 68 (52%) pts, IVC filter only was inserted to 6 (5%) pts and 56 (43%)pts were treated with both modalities). 15 pts developed complications secondary to anticoagulation(5 brain haemorrhage , 6 bleeding in other locations and 4 thrombocytopenia). On univariate analysis risk factor associated with development of VTE after starting adjuvant TMZ treatment were: sex, prior history of venous thrombosis, poor KPS, requiring assistive device for ambulation, paresis, high BMI, pre chemotherapy WBC counts, and various medications (including anticoagulation, blood pressure drugs, anti-acid drugs and corticosteroids) (p<0.05). On multivariate analysis sex, poor KPS, high BMI, history of VTE and use of corticosteroids were significant risk factors for the development of VTE (P<0.05). Conclusions: VTE is a common complication of GB and can occur during the course of the disease. Factors associated with increased risk have been identified and will be useful in developing risk models in this patient population.

An association study of asthma and total serum immunoglobin E levels for Toll‐like receptor polymorphisms in a Japanese population

Risk Factors and Prognosis Value of Venous Thromboembolism in Patients with Advanced Non-Small Cell Lung Cancer: a Case-Control Study

Venous thromboembolism in non-small-cell lung cancer patients:Report of 15 cases

Venous Thromboembolism (VTE) and Glioblastoma.

High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma

Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A.

Early‐onset venous thromboembolisms in newly diagnosed non‐promyelocytic acute myeloid leukemia patients undergoing intensive induction chemotherapy

Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With Chemotherapy

Higher incidence of venous thromboembolism associated with increasing lines of treatment in heavily treated ovarian cancer patients

Adherence to early mobilisation: Key for successful enhanced recovery after liver resection.

Venous thromboembolic events in T-cell lymphoma patients: Incidence, risk factors and clinical features

A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors

Catheter and Non-Catheter-Related Venous Thromboembolism in Cancer Patients: Survival, Anticoagulation Efficacy, and Safety

Prevalence and Prognostic Role of Lymphedema in Patients with Deep Venous Thrombosis and Thrombophlebitis

Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study

Thrombosis and bleeding in hematological malignancy

Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism

Clinical Analysis of the Gynecologic Oncology with Acute Deep Venous Thrombosis of Lower Extremities

Risk of venous thromboembolism after discontinuing prophylactic or therapeutic anticoagulation in patients with haematologic malignancies because of thrombocytopenia

Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer

Role of SCA2 mutations in early‐ and late‐onset dopa‐responsive parkinsonism